FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2233795112> ?p ?o ?g. }

• W2233795112 endingPage "1354" @default.
• W2233795112 startingPage "1352" @default.
• W2233795112 abstract "Mesothelioma is an asbestos-related malignancy that begins in the pleural lining of the lung, pericardium, peritoneum, or testes. Early-stage pleural mesothelioma can be resected, but almost always recurs. Many patients are diagnosed at an advanced stage of disease, at which point surgery has no role. Since 2003, the standard treatment for unresectable disease has been combination chemotherapy with cisplatin and pemetrexed. 1 Vogelzang NJ Rusthoven JJ Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21: 2636-2644 Crossref PubMed Scopus (2493) Google Scholar Despite many attempts, until now, no regimen has further improved survival. Although addiction to oncogenes occurs in some cancers, most molecular alterations in mesothelioma occur in tumour suppressors and the corresponding drug target is unclear. Research is underway to exploit some of the most common molecular aberrations and dependencies in mesothelioma. 2 Ladanyi M Zauderer MG Krug LM et al. New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment. Clin Cancer Res. 2012; 18: 4485-4490 Crossref PubMed Scopus (64) Google Scholar , 3 Pastan I Hassan R Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res. 2014; 74: 2907-2912 Crossref PubMed Scopus (164) Google Scholar , 4 Stahel RA Weder W Felley-Bosco E et al. Searching for targets for the systemic therapy of mesothelioma. Ann Oncol. 2015; 26: 1649-1660 Crossref PubMed Scopus (32) Google Scholar For example, the important role of vascular endothelial growth factor (VEGF) signalling in mesothelioma has been known for many years, 5 Ohta Y Shridhar V Bright RK et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer. 1999; 81: 54-61 Crossref PubMed Scopus (312) Google Scholar , 6 Strizzi L Catalano A Vianale G et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol. 2001; 193: 468-475 Crossref PubMed Scopus (312) Google Scholar but studies of single-drug VEGF inhibitors were disappointing. 7 Buikhuisen WA Burgers JA Vincent AD et al. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. Lancet Oncol. 2013; 14: 543-551 Summary Full Text Full Text PDF PubMed Scopus (89) Google Scholar , 8 Dubey S Janne PA Krug L et al. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol. 2010; 5: 1655-1661 Summary Full Text Full Text PDF PubMed Scopus (97) Google Scholar , 9 Jahan T Gu L Kratzke R et al. Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer. 2012; 76: 393-396 Summary Full Text Full Text PDF PubMed Scopus (57) Google Scholar , 10 Nowak AK Millward MJ Creaney J et al. A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma. J Thorac Oncol. 2012; 7: 1449-1456 Summary Full Text Full Text PDF PubMed Scopus (72) Google Scholar Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trialAddition of bevacizumab to pemetrexed plus cisplatin significantly improved OS in malignant pleural mesothelioma at the cost of expected manageable toxic effects, therefore it should be considered as a suitable treatment for the disease. Full-Text PDF" @default.
• W2233795112 created "2016-06-24" @default.
• W2233795112 creator A5014084163 @default.
• W2233795112 date "2016-04-01" @default.
• W2233795112 modified "2023-10-18" @default.
• W2233795112 title "A new standard for malignant pleural mesothelioma" @default.
• W2233795112 cites W1969194497 @default.
• W2233795112 cites W2012492706 @default.
• W2233795112 cites W2014943535 @default.
• W2233795112 cites W2065538551 @default.
• W2233795112 cites W2068264084 @default.
• W2233795112 cites W2081508876 @default.
• W2233795112 cites W2102627969 @default.
• W2233795112 cites W2122981879 @default.
• W2233795112 cites W2124863710 @default.
• W2233795112 cites W2159020660 @default.
• W2233795112 cites W2160676107 @default.
• W2233795112 cites W2167527173 @default.
• W2233795112 cites W2174280796 @default.
• W2233795112 doi "https://doi.org/10.1016/s0140-6736(15)01311-2" @default.
• W2233795112 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5464401" @default.
• W2233795112 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26719231" @default.
• W2233795112 hasPublicationYear "2016" @default.
• W2233795112 type Work @default.
• W2233795112 sameAs 2233795112 @default.
• W2233795112 citedByCount "9" @default.
• W2233795112 countsByYear W22337951122016 @default.
• W2233795112 countsByYear W22337951122017 @default.
• W2233795112 countsByYear W22337951122018 @default.
• W2233795112 countsByYear W22337951122019 @default.
• W2233795112 countsByYear W22337951122020 @default.
• W2233795112 countsByYear W22337951122022 @default.
• W2233795112 crossrefType "journal-article" @default.
• W2233795112 hasAuthorship W2233795112A5014084163 @default.
• W2233795112 hasBestOaLocation W22337951122 @default.
• W2233795112 hasConcept C121608353 @default.
• W2233795112 hasConcept C126322002 @default.
• W2233795112 hasConcept C142724271 @default.
• W2233795112 hasConcept C143998085 @default.
• W2233795112 hasConcept C2776694085 @default.
• W2233795112 hasConcept C2777240266 @default.
• W2233795112 hasConcept C2777407522 @default.
• W2233795112 hasConcept C2778239845 @default.
• W2233795112 hasConcept C2778995398 @default.
• W2233795112 hasConcept C2779399171 @default.
• W2233795112 hasConcept C502942594 @default.
• W2233795112 hasConcept C71924100 @default.
• W2233795112 hasConceptScore W2233795112C121608353 @default.
• W2233795112 hasConceptScore W2233795112C126322002 @default.
• W2233795112 hasConceptScore W2233795112C142724271 @default.
• W2233795112 hasConceptScore W2233795112C143998085 @default.
• W2233795112 hasConceptScore W2233795112C2776694085 @default.
• W2233795112 hasConceptScore W2233795112C2777240266 @default.
• W2233795112 hasConceptScore W2233795112C2777407522 @default.
• W2233795112 hasConceptScore W2233795112C2778239845 @default.
• W2233795112 hasConceptScore W2233795112C2778995398 @default.
• W2233795112 hasConceptScore W2233795112C2779399171 @default.
• W2233795112 hasConceptScore W2233795112C502942594 @default.
• W2233795112 hasConceptScore W2233795112C71924100 @default.
• W2233795112 hasIssue "10026" @default.
• W2233795112 hasLocation W22337951121 @default.
• W2233795112 hasLocation W22337951122 @default.
• W2233795112 hasLocation W22337951123 @default.
• W2233795112 hasLocation W22337951124 @default.
• W2233795112 hasOpenAccess W2233795112 @default.
• W2233795112 hasPrimaryLocation W22337951121 @default.
• W2233795112 hasRelatedWork W2007997953 @default.
• W2233795112 hasRelatedWork W2009040992 @default.
• W2233795112 hasRelatedWork W2083305999 @default.
• W2233795112 hasRelatedWork W2097943006 @default.
• W2233795112 hasRelatedWork W2162580433 @default.
• W2233795112 hasRelatedWork W2166686383 @default.
• W2233795112 hasRelatedWork W2603203952 @default.
• W2233795112 hasRelatedWork W2953220268 @default.
• W2233795112 hasRelatedWork W2953636941 @default.
• W2233795112 hasRelatedWork W3042471957 @default.
• W2233795112 hasVolume "387" @default.
• W2233795112 isParatext "false" @default.
• W2233795112 isRetracted "false" @default.
• W2233795112 magId "2233795112" @default.
• W2233795112 workType "article" @default.